Dimebon attenuates methamphetamine, but not MPTP, striatal dopamine depletion.

Title

Dimebon attenuates methamphetamine, but not MPTP, striatal dopamine depletion.

Creator

Geldenhuys Werner J; Darvesh Altaf S; Dluzen Dean E

Publisher

Neurochemistry international

Date

2012
2012-06

Description

Dimebon is an anti-histamine with central nervous system activity. In this report the effects of dimebon as a neuroprotectant in animal models of Parkinson's disease were tested as assessed in methamphetamine- and MPTP-induced striatal dopaminergic toxicity. Dimebon (1mg/kg) administered at 30 min prior to methamphetamine (40mg/kg) significantly reduced the amount of striatal dopamine depletion in mice, without altering the initial methamphetamine-induced increase in body temperature. In contrast, dimebon at either 1 or 25mg/kg administered at 30 min prior to MPTP (35 mg/kg) was unable to prevent MPTP-induced striatal dopamine loss as determined at 7 days post-methamphetamine/MPTP. These data suggest that dimebon may be exerting a neurotoxin specific neuroprotective effect upon the striatal dopaminergic system and may serve as an important tool for discriminating the mechanistic basis of these two dopaminergic neurotoxins.

Subject

Animals; Corpus Striatum/*drug effects/metabolism; Dopamine/*metabolism; Drug Synergism; Inbred C57BL; Indoles/*pharmacology; Methamphetamine/*pharmacology; Mice

Rights

Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).

Pages

806–808

Issue

8

Volume

60

Citation

Geldenhuys Werner J; Darvesh Altaf S; Dluzen Dean E, “Dimebon attenuates methamphetamine, but not MPTP, striatal dopamine depletion.,” NEOMED Bibliography Database, accessed June 23, 2021, https://neomed.omeka.net/items/show/3709.

Social Bookmarking